The immune system of pregnant women fluctuate throughout the course of the nine months carrying the child or children, this is an established fact. However, the sex of the baby as the factor has always been more of conjecture than anything else. A new study states that this isn’t the case at all and that the sex of the baby does determine the immunity of the mother.
During pregnancy, it’s normal for women to experience several changes that affect their mood, their physical attributes, and their habits. This is only to be expected since the fluctuating hormones are causing havoc in their systems. As far as their immunity goes, Ohio State University Wexner Medical Center researchers recently discovered that women carrying female fetuses tend to be more prone to inflammation, MedicalXpress reports.
According to Amanda Mitchell, one of the researchers behind the study, their research involved looking into the cases of 80 pregnant women. The tests involved measuring the levels of cytokine in their blood as well as their immune cells.
"While women didn't exhibit differences in blood cytokine levels based on fetal sex, we did find that the immune cells of women carrying female fetuses produced more pro-inflammatory cytokines when exposed to bacteria,” Mitchell said. “This means that women carrying female fetuses exhibited a heightened inflammatory response when their immune system was challenged, compared to women carrying male fetuses."
This can be a huge concern because inflammation can add stress to an already strained body, Tech Times notes. The system of a pregnant subject regularly undergoes several transitions that are normally alien. If inflammation persists, it could harm both the mother and the baby.
On that note, Mitchell added that inflammation can be easily managed by sticking to routine habits that are often encouraged by doctors. With proper exercise, a healthy diet full of leafy vegetables and fruits, and frequent meditation, inflammation can be managed.


FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand
U.S. Reveals 2026 Medicare Star Ratings: Aetna, UnitedHealth Lead in Quality Scores
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown
CDC Vaccine Review Sparks Controversy Over Thimerosal Study Citation
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Lost in space: MethaneSat failed just as NZ was to take over mission control – here’s what we need to know now
Neuralink Expands Brain Implant Trials with 12 Global Patients
Tabletop particle accelerator could transform medicine and materials science
NASA and Roscosmos Chiefs Meet in Florida to Discuss Moon and ISS Cooperation
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 



